Photocure Trials at EAU 2026 Target Personalized Bladder Cancer Care
Event summary
- Photocure presented two 'trial in progress' studies at the EAU 2026 congress in London, focusing on non-muscle invasive bladder cancer (NMIBC).
- The CUT-less trial (NCT05962541) aims to omit second-look TURBT by combining MRI (VI-RADS) with blue-light TURBT, enrolling 327 patients over 3 years.
- The second trial (NCT06525571) evaluates urinary minimal residual disease (MRD) using UroAmp, comparing blue light vs. white light cystoscopy in 200 high-risk NMIBC patients.
- Photocure's Hexvix® product was prominently featured in the EAU scientific program, highlighting its role in blue light cystoscopy.
The big picture
Photocure's trials at EAU 2026 reflect a broader push toward precision diagnostics in bladder cancer, where minimally invasive procedures and genomic profiling are reshaping treatment paradigms. The focus on cost-utility and recurrence-free survival aligns with healthcare systems' demand for economically sustainable, high-value care. If successful, these trials could position Photocure as a leader in personalized bladder cancer management.
What we're watching
- Trial Outcomes
- Whether the CUT-less trial can validate the omission of second-look TURBT, potentially reducing procedural burden and costs.
- Diagnostic Integration
- How the combination of MRI (VI-RADS) and blue light cystoscopy will impact NMIBC treatment pathways.
- Market Adoption
- The pace at which Photocure can expand the use of Hexvix®/Cysview® in high-risk NMIBC surveillance.
Related topics